Obstructive and restrictive pulmonary dysfunctions in Parkinson's disease

Journal of the Neurological Sciences

Volumn 138, Issue 1-2, 1996, Pages 114-119

  Sabaté, Magdalena ^b   González, Isidro ^b   Ruperez, Felix ^b   Rodríguez, Manuel ^a  

^a UNIVERSIDAD DE LA LAGUNA   (Spain)

^b HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BRADYKINESIA; CONTROLLED STUDY; FEMALE; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PLETHYSMOGRAPHY; PRIORITY JOURNAL; RIGIDITY; VITAL CAPACITY;

EID: 0343026335     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0022-510X(96)00003-2     Document Type: Article

References (33)

1. Hoehn, M.M., Yahr, M.D. (1967) Parkinsonism: onset, progression and mortality. Neurology, 17:427-442.
2. Vincken, W.G., Gauthier, S.G., Dollfuss, R.E., Hanson, R.E., Darauay, C.M., Cosio, M.G. (1984) Involvement of upper-airway muscles in extrapyramidal disorders. N. Engl. J. Med., 311: 438-442.
3. Hovestadt, A., Bogaard, J.M., Meerwaldt, J.D., van der Meché, F.G.A. (1989) Pulmonary function in Parkinson's disease. J. Neurol. Neurosurg. Psychiat., 52: 329-333.
4. Ferris, B.G. (1978) Epidemiology standardization project. III. Recommended standardized procedures for pulmonary function testing. Am. Rev. Respir. Dis., 118: 55-88.
5. Despas, P.J., Leroux, M., Macklem, P.T. (1972) Site of airway obstruction in asthma as determined by measuring maximal expiratory flow breathing air and helium-oxygen mixture. J. Clin. Invest., 51: 3235-3243.
6. Knudson, R.J., Slating, R.C., Lehowitz, M.D. and Burrows, B. (1976) The maximal espiratory flow-volume curve. Normal standards, variability and effects of age. Am. Rev. Respir. Dis., 113: 587-600.
7. Morris, J.F. (1975) Normal values and evaluation of forced end-expiratory flow. Am. Res. Respir. Dis., 111: 755-762.
8. Black, L.F., Hyatt, R.E. (1969) Maximal respiratory pressures: normal values and relationship to age and sex. Am. Rev. Respir. Dis., 99: 696-702.
9. Rinne, U.K. (1981) Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson's disease. Lancet, i: 44.
10. LaWitt, P.A., Calne, D.B. (1981) Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson's disease. Lancet, i:45.
11. Besser, G.M., Wass, J.A.H. (1981) Pleuropulmonary shadows on bromocriptine. Lancet, y: 323.
12. Dupont, E., de Fine Olivarius, B., Strong, M.J. (1982) Bromocriptine-induced collagenosis-like symptomatology in Parkinson's disease. Lancet, y: 850-851.
13. Vergeret, J., Barat, M., Taytard, A., Bellevert, P., Domblides, Ph., Douvier, J., Fléovr, P. (1984) Fibrose pleuropulmonaire et bromocriptine. Sem. Hop. Paris, 60: 740-741.
14. Wiggins, J., Skinner, C. (1986) Bromocriptine-induced pleuropulmonary fibrosis. Thorax. 41: 328-330.
15. Tornling, G., Unge, G., Axelsson, G., Noring, L., Granerus, A.K. (1986) Pleuropulmonary reactions in patients on bromocriptine treatment. Eur. J. Respir. Dis., 68: 35-38.
16. McElvany, N.G., Wilcox, P.G., Churg, A.M., Fleetham, J.A. (1988) Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease. Arch. Intern. Med., 148: 2231-2236.
17. Kinnunen, E., Viljanen, A. (1988) Pleuropulmonary involvement during bromocriptine treatment. Chest, 94: 1034-1036.
18. Melmed, S., Braunstein, G. (1989) Bromocriptine and pleuropulmonary disease. Arch. Intern. Med., 149: 258-259.
19. Taal, B.C., Spierings, E.L., Hilvering, C. (1983) Pleuropulmonary changes with chronic and excessive intake of ergotamine. Thorax, 38: 396-398.
20. Frans, E., Dom, R., Demedts, M. (1992) Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline. Eur. Respir. J., 5: 263-265.
21. Lilker, E.S., Woolf, C.A. (1968) Pulmonary function in Parkinson's syndrome: the effect of thalotomy. Can. Med. Assoc. J., 99: 752-757.
22. Neu, H.C., Connolly, J.J., Schwertley, F.W., Ladwig, H.A., Brody, AW. (1967) Obstructive respiratory dysfunction in Parkinsonian patients. Am. Rev. Respir. Dis., 95: 33-47.
23. Obenour, W.H., Stevens, P.M., Cohen, A.A., McCutchen, J.J. (1972) The causes of abnormal pulmonary function in Parkinson's disease. Am. Rev. Respir. Dis. 105: 382-387.
24. Guindi, G.M., Bannister, R., Gibson, W.R.P., Payne, J.K. (1981) Laryngeal electromyography in multiple system atrophy with autonomic failure. J. Neurol. Neurosurg. Psychiatry 44: 49-53.
25. Estenne, M., Hubert, M., De Troyer, A. (1984) Respiratory-muscle involvement in Parkinson's disease. New Eng. J. Med. 311: 1516.
26. Gross, M., Bannister, R., Godwin-Ansten, R. (1972) Orthostatic hypotension in Parkinson's disease. Lancet, 1:174-6.
27. Appenzeller, O., Goss, J.E. (1974) Autonomic deficits in Parkinson's syndrome. Arch. Neurol. 24: 50-7.
28. Rajput, A.H., Rozdilsky, B. (1976) Dysautonomia in Parkinsonism: a clinicopathological study. J. Neurol. Neurosurg. Psychiat., 39:1092-100.
29. Goetz, C.G., Lutge, W., Tanner, C.M. (1986) Autonomic dysfunction in Parkinson's disease. Neurology 36: 73-5.
30. Rodríguez, M., Sabaté, M. and Troncoso, E. Time and frequency domain analysis for the assessment of heart autonomic control in Parkinson's disease. Am. J. Physiol. (submitted for publication).
31. Fink, M.E., Klebanoff, L.M., Lennihan, L., Fahn, S. (1989) Acute respiratory failure during drug manipulation in patients with Parkinson disease. Neurology 39 (Suppl 1): 348.
32. Riley, D.E., Grossman, G. and Martin, L. (1992) Acute respiratory failure from dopamine agonist withdrawal. Neurology 42: 1843-1844.
33. Schenkman, M. and Butler, R.B. (1989) A model for multisystem avaluation treatment of individuals with Parkinson's disease. Phys. Ther., 69: 932-943.